Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer
Copyright © 2023 Elsevier B.V. All rights reserved..
Dasatinib (DST) is a tyrosine kinase inhibitor with established antiproliferative activity in Triple-negative breast cancer. Conventional treatment strategies with DST have several pitfalls related to the development of resistance, lower cellular uptake and unwanted adverse effects. To address these issues, we have prepared P-selectin-targeted nanoparticles of DST with fucoidan (FUC) as a ligand. Poly lactide-co-glycolide nanoparticles of DST were coated with chitosan (CH) and FUC via electrostatic interaction (DST-CH-FUC-NPs). The mean particle size of 210.36 ± 0.66 nm and a polydispersity index of 0.234 ± 0.013 was observed for DST-CH-FUC-NPs. TEM and FTIR analysis proved CH coating followed by an FUC layer on nanoparticles. DST-CH-FUC-NPs showed a sustained release profile up to 120 h and 2.9 times less hemolytic potential than free DST suspension. DST-CH-FUC-NPs demonstrated 8-fold higher cytotoxicity compared to free DST in MDA-MB-231 cells. Rhodamine-CH-FUC- NPs showed 19 times and 3 times higher cellular uptake than free Rhodamine and Rhodamine-CH-NPs, respectively. DST-CH-FUC-NPs also displayed increased ROS production and mitochondrial membrane potential damage. Apoptosis study revealed a 7.5-fold higher apoptosis index for DST-CH-FUC-NPs than free DST. Subsequently, the DST-CH-FUC-NPs showed increased inhibition of cell migration, where approximately 5 % wound closure was noted. Further, DST-CH-FUC-NPs confirmed higher disruption of lysosomal membrane integrity, which is well correlated with apoptosis results. In addition, developed NPs were nontoxic on MCF 10 A normal cells. All these findings suggest that fabricated DST-CH-FUC-NPs are promising biocompatible carriers for tumor-targeted delivery and enhanced efficacy of dasatinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:233 |
|---|---|
| Enthalten in: |
Colloids and surfaces. B, Biointerfaces - 233(2023) vom: 04. Jan., Seite 113631 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saren, Brojendra Nath [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9012-76-4 |
|---|
| Anmerkungen: |
Date Completed 07.12.2023 Date Revised 07.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.colsurfb.2023.113631 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364710152 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364710152 | ||
| 003 | DE-627 | ||
| 005 | 20231226100008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.colsurfb.2023.113631 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364710152 | ||
| 035 | |a (NLM)37979483 | ||
| 035 | |a (PII)S0927-7765(23)00516-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saren, Brojendra Nath |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2023 | ||
| 500 | |a Date Revised 07.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Dasatinib (DST) is a tyrosine kinase inhibitor with established antiproliferative activity in Triple-negative breast cancer. Conventional treatment strategies with DST have several pitfalls related to the development of resistance, lower cellular uptake and unwanted adverse effects. To address these issues, we have prepared P-selectin-targeted nanoparticles of DST with fucoidan (FUC) as a ligand. Poly lactide-co-glycolide nanoparticles of DST were coated with chitosan (CH) and FUC via electrostatic interaction (DST-CH-FUC-NPs). The mean particle size of 210.36 ± 0.66 nm and a polydispersity index of 0.234 ± 0.013 was observed for DST-CH-FUC-NPs. TEM and FTIR analysis proved CH coating followed by an FUC layer on nanoparticles. DST-CH-FUC-NPs showed a sustained release profile up to 120 h and 2.9 times less hemolytic potential than free DST suspension. DST-CH-FUC-NPs demonstrated 8-fold higher cytotoxicity compared to free DST in MDA-MB-231 cells. Rhodamine-CH-FUC- NPs showed 19 times and 3 times higher cellular uptake than free Rhodamine and Rhodamine-CH-NPs, respectively. DST-CH-FUC-NPs also displayed increased ROS production and mitochondrial membrane potential damage. Apoptosis study revealed a 7.5-fold higher apoptosis index for DST-CH-FUC-NPs than free DST. Subsequently, the DST-CH-FUC-NPs showed increased inhibition of cell migration, where approximately 5 % wound closure was noted. Further, DST-CH-FUC-NPs confirmed higher disruption of lysosomal membrane integrity, which is well correlated with apoptosis results. In addition, developed NPs were nontoxic on MCF 10 A normal cells. All these findings suggest that fabricated DST-CH-FUC-NPs are promising biocompatible carriers for tumor-targeted delivery and enhanced efficacy of dasatinib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chitosan | |
| 650 | 4 | |a Fucoidan | |
| 650 | 4 | |a P-selectin | |
| 650 | 4 | |a Targeted nanoparticles | |
| 650 | 7 | |a Dasatinib |2 NLM | |
| 650 | 7 | |a RBZ1571X5H |2 NLM | |
| 650 | 7 | |a fucoidan |2 NLM | |
| 650 | 7 | |a 9072-19-9 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Rhodamines |2 NLM | |
| 650 | 7 | |a Chitosan |2 NLM | |
| 650 | 7 | |a 9012-76-4 |2 NLM | |
| 700 | 1 | |a Mahajan, Srushti |e verfasserin |4 aut | |
| 700 | 1 | |a Aalhate, Mayur |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Essha |e verfasserin |4 aut | |
| 700 | 1 | |a Maji, Indrani |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ujala |e verfasserin |4 aut | |
| 700 | 1 | |a Guru, Santosh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Pankaj Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Colloids and surfaces. B, Biointerfaces |d 1994 |g 233(2023) vom: 04. Jan., Seite 113631 |w (DE-627)NLM09266623X |x 1873-4367 |7 nnns |
| 773 | 1 | 8 | |g volume:233 |g year:2023 |g day:04 |g month:01 |g pages:113631 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.colsurfb.2023.113631 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 233 |j 2023 |b 04 |c 01 |h 113631 | ||